RIVAROXABAN IN LONG-TERM PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
In patients with acute coronary syndrome (ACS), the combination of dual antiplatelet therapy (DAT) and parenteral anticoagulants (unfractionated or low molecular weight heparin or fondaparinux) in the acute (inpatient) phase of the disease correlates with the most significant reduction in cardiovasc...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2017-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/1767 |